Bio­phar­ma man­u­fac­tur­ing ‘tur­bu­lence’ boosts in­quiries for In­dia-based providers, lo­cal CD­MO ex­ecs say

In­dia-based CD­MOs have de­tect­ed an uptick in bio­phar­ma client in­ter­est in their bi­o­log­ics and ear­ly-phase clin­i­cal of­fer­ings – and these man­u­fac­tur­ers are ac­cord­ing­ly ad­just­ing their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.